Immutep Reports Positive Final Efficacy Data from TACTI-mel Trial in MelanomaGlobeNewsWire • 10/15/19
Immutep Announces Expansion of Part A of TACTI-002 Phase II Clinical Trial due to Positive Interim DataGlobeNewsWire • 09/26/19